2-fluoro-N-[4-(8-nitroquinolin-4-yl)oxyphenyl]-5-(trifluoromethyl)benzamide | 1313019-82-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-N-[4-(8-nitroquinolin-4-yl)oxyphenyl]-5-(trifluoromethyl)benzamide
• CAS: 1313019-82-7
• 化学式: C₂₃H₁₃F₄N₃O₄
• 分子量: 471.368
• InChiKey: VQQYSWPPSHQZEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-氯-8-硝基喹啉 在 吡啶 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 2-fluoro-N-[4-(8-nitroquinolin-4-yl)oxyphenyl]-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf

  摘要：

  STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.04.007

文献信息

• [EN] AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME<br/>[FR] AGONISTES DE PROTÉINE TYROSINE PHOSPHATASE-1 CONTENANT UN DOMAINE D'HOMOLOGIE SRC-2 ET PROCÉDÉS DE TRAITEMENT L'EMPLOYANT
  申请人：UNIV NAT TAIWAN

  公开号：WO2013020014A1

  公开（公告）日：2013-02-07

  The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase- 1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.

  本发明提供了式I、II或III的新化合物，这些化合物具有Src同源-2含有蛋白酪氨酸磷酸酶-1（SHP-1）激动剂活性。同时，本发明还提供了使用式I、II或III的化合物进行治疗的方法。
• AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME
  申请人：National Taiwan University

  公开号：EP2739139B1

  公开（公告）日：2019-09-25
• US9090617B1
  申请人：——

  公开号：US9090617B1

  公开（公告）日：2015-07-28
• US9216950B2
  申请人：——

  公开号：US9216950B2

  公开（公告）日：2015-12-22
• Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf
  作者：Kuen-Feng Chen、Wei-Tien Tai、Jui-Wen Huang、Cheng-Yi Hsu、Wei-Lin Chen、Ann-Lii Cheng、Pei-Jer Chen、Chung-Wai Shiau

  DOI：10.1016/j.ejmech.2011.04.007

  日期：2011.7

  STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors. (C) 2011 Elsevier Masson SAS. All rights reserved.